Findings

What do systematic reviews say?

166 questions · 177 findings · 9 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 86 · 48.6%GRADE not reported 8 · 4.5%Very low 44 · 24.9%Low 38 · 21.5%Moderate 1 · 0.6%High 0 · 0%

Intervention not reported

Diabetes‐related mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Diabetes‐related morbidity

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Patient satisfaction

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events: a. hypoglycaemia (% of participants)

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 503 participants
Low

Intervention not reported

HbA1c, change from baseline (%)

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Low

Intervention not reported

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Patient satisfaction

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events: a. mild hypoglycaemia (episodes per participant)

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 239 participants
Low

Intervention not reported

HbA1c, change from baseline (%)

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 316 participants
Low

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Diabetes‐related mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life [measured by the validated questionnaire SF‐36]

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 425 participants
GRADE not reported

Intervention not reported

Development and worsening of Graves' ophthalmopathy [examination by ophthalmologists]

The intervention may leads to higher development and worsening of Graves' ophthalmopathy [examination by… (low certainty).

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
RR 1.94 [1.4, 2.7]
2 studies · 417 participants
Low

Intervention not reported

Individuals in euthyroid state [measured by serum thyroid hormone levels within the normal range]

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Intervention not reported

Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment]

It is very uncertain whether the intervention changes recurrence of hyperthyroidism (relapse) [measured by serum thyroid… (very low certainty).

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
RR 0.2 [0.01, 2.66]
2 studies · 417 participants
Very low

Intervention not reported

Adverse events other than development or worsening of Graves' disease (a) Hypothyroidism [measured by TSH and/or thyroid hormones] (b) Drug reactions

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Very low

Intervention not reported

All‐cause mortality

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 425 participants
GRADE not reported

Intervention not reported

Socioeconomic effects [costs per patient, based on the official hospital reimbursement system in Sweden]

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Intervention not reported

Diabetes and non‐diabetes related morbidity · peri‐ or postmenopausal women with type 1 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Hormone replacement therapy for women with type 1 diabetes mellitus 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found